ArticleMolecular cancer therapeutics2021

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Brion W Murray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.